Matrix metallopropteinases in heart failure

Current Topics in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 1181-1191

  Tousoulis, Dimitris ^a   Kampoli, Anna Maria ^a   Papageorgiou, Nikolaos ^a   Antoniades, Charalambos ^a   Siasos, Gerasimos ^a   Latsios, George ^a   Tsiamis, Eleftherios ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Clinical implications; Dysfunction; Heart failure; Left ventricle remodeling; Matrix metalloproteinases; Oxidative stress

Indexed keywords

ANGIOTENSIN II; ANTIOXIDANT; CAPTOPRIL; CP 471474; EPIMEDIUM EXTRACT; GELATINASE A; GELATINASE B; I KAPPA B; INTERSTITIAL COLLAGENASE; LEVOSIMENDAN; LISINOPRIL; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PG 530742; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PRAVASTATIN; PROPRANOLOL; RAMIPRILAT; REACTIVE OXYGEN METABOLITE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANOXIA; APOPTOSIS; ARTICLE; DOWN REGULATION; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; FIBROSIS; GENE THERAPY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; REOXYGENATION; STEM CELL TRANSPLANTATION;

EID: 84861160895     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611208011181     Document Type: Article

References (83)

1. Lip, G.; Gibbs, C.; Beevers, D. ABC of heart failure: aetiology. BMJ., 2000, 320(7227), 104-107.
2. Jackson, G.; Gibbs, C.R.; Davies, M.K.; Lip, G.Y. ABC of heart failure. Pathophysiology. BMJ., 2000, 320(7228), 167-170.
3. Aronow, W.S. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. Cardiol. Rev., 2006, 14(3), 108-124.
4. Braunschweig, F.; Cowie, M.R.; Auricchio, A. What are the costs of heart failure? Europace, 2011, 13 Suppl. 2, ii13-7.
5. Nilsson, B.B.; Hellesnes, B.; Westheim, A.; Risberg, M.A. Group-based aerobic interval training in patients with chronic heart failure: Norwegian Ullevaal Model. Phys. Ther., 2008, 88(4), 523-535.
6. Tousoulis, D.; Papageorgiou, N.; Briasoulis, A.; Androulakis, E.; Charakida, M.; Tsiamis, E.; Stefanadis, C. Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies. Heart. Fail. Rev., 2012, 17(1), 65-79.
7. Tousoulis, D.; Kampoli, A.M.; Siasos, G.; Stefanadi, E.; Antoniades, C.; Papavassiliou, A.G.; Stefanadis, C. Circulating biomarkers for the diagnosis and prognosis of heart failure. Curr. Med. Chem., 2009, 16(29), 3828-3840.
8. Pei, D.; Kang, T.; Qi, H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem., 2000, 275(43), 33988-33997.
9. Spinal, F.G. Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function. Physiol. Rev., 2007, 87(4),1285-1342.
10. Van Lint, P.; Libert, C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol., 2007, 82(6), 1375-1381.
11. Trexler, M.; Briknarová, K.; Gehrmann, M.; Llinás, M.; Patthy, L. Peptide ligands for the fibronectin type II modules of matrix metalloproteinase 2 (MMP-2). J. Biol. Chem., 2003, 278(14), 12241-12246.
12. Chen, L.C.; Noelken, M.E.; Nagase, H. Disruption of the cysteine- 75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin 1). Biochemistry, 1993, 32(39), 10289-10295.
13. Park, A.J.; Matrisian, L.M.; Kells, A.F.; Pearson, R.; Yuan, Z.Y.; Navre, M. Mutational analysis of the transin (rat stromelysin) autoinhibitor region demonstrates a role for residues surrounding the cysteine switch. J. Biol. Chem., 1991, 266(3), 1584-1590.
14. Zucker, S.; Pei, D.; Cao, J.; Lopez-Otin, C. Membrane type-matrix metalloproteinases (MT-MMP). Curr. Top. Dev. Biol., 2003, 54, 1-74.
15. Yang, Z.; Strickland, D.K.; Bornstein, P. Extracellular MMP-2 levels are regulated by the low-density lipoprotein-related scavenger receptor and thrombospondin 2. J. Biol. Chem., 2001, 276(11), 8403-8408.
16. Takahashi, C.; Sheng, Z.; Horan, T.P.; Kitayama, H.; Maki, M.; Hitomi, K.; Kitaura, Y.; Takai, S.; Sasahara, R.M.; Horimoto, A.; Ikawa, Y.; Ratzkin, B.J.; Arakawa, T.; Noda, M. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl. Acad. Sci. USA., 1998, 95(22), 13221-13226.
17. Rouet-Benzineb, P.; Buhler, J.M.; Dreyfus, P.; Delcourt, A.; Dorent, R.; Perennec, J.; Crozatier, B.; Harf, A.; Lafuma, C. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur. J. Heart. Fail., 1999, 1(4), 337-352.
18. Thomas, C.V.; Coker, M.L.; Zellner, J.L.; Handy, J.R.; Crumbley, A.J. III.; Spinale, F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation, 1998, 97(17), 1708-1715.
19. Coker, M.L.; Doscher, M.A.; Thomas, C.V.; Galis, Z.S.; Spinale, F.G. Matrix metalloproteinase activity and expression in isolated LV myocyte preparations. Am. J. Physiol., 1999, 277 (2 Pt 2), H777-787.
20. Herpel, E.; Singer, S.; Flechtenmacher, C.; Pritsch, M.; Sack, F.U.; Hagl, S.; Katus, H.A.; Haass, M.; Otto, H.F.; Schnabel, P.A. Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies. Virchows. Arch., 2005, 446(4), 369-378.
21. Sluijter, J.P.; Pulskens, W.P.; Schoneveld, A.H.; Velema, E.; Strijder, C.F.; Moll, F.; de Vries, J.P.; Verheijen, J.; Hanemaaijer, R.; de Kleijn, D.P.; Pasterkamp, G. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke, 2006, 37(1), 235-239.
22. Spinale, F.G.; Coker, M.L.; Heung, L.J.; Bond, B.R.; Gunasinghe, H.R.; Etoh, T.; Goldberg, A.T.; Zellner, J.L.; Crumbley, A.J. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation, 2000, 102(16), 1944-1949.
23. Klotz, S.; Foronjy, R.F.; Dickstein, M.L.; Gu, A.; Garrelds, I.M.; Danser, A.H.; Oz, M.C.; D'Armiento, J.; Burkhoff, D. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation, 2005, 112(3), 364-374.
24. Mukherjee, R.; Herron, A.R.; Lowry, A.S.; Stroud, R.E.; Stroud, M.R.; Wharton, J.M.; Ikonomidis, J.S.; Crumbley, A.J. 3rd; Spinale, F.G.; Gold, M.R. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am. J. Cardiol., 2006, 97(4), 532-537.
25. Deschamps, A.M.; Spinale, F.G. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc. Res., 2006, 69(3), 666-676.
26. Liacini, A.; Sylvester, J.; Li, W.Q.; Zafarullah, M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix. Biol., 2002, 21(3), 251-562.
27. Okamoto, T.; Akaike, T.; Sawa, T.; Miyamoto, Y.; van der Vliet, A.; Maeda, H. Activation of matrix metalloproteinases by per oxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem., 2001, 276(31), 29596-29602.
28. Kameda, K.; Matsunaga, T.; Abe, N.; Hanada, H.; Ishizaka, H.; Ono, H.; Saitoh, M.; Fukui, K.; Fukuda, I.; Osanai, T.; Okumura, K. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur. J. Heart., 2003, 24(24), 2180-2185.
29. Siwik, D.A.; Pagano, P.J.; Colucci, W.S. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am. J. Physiol. Cell. Physiol., 2001, 280(1), 53-60.
30. Chen, K.; Li, D.; Zhang, X.; Hermonat, P.L.; Mehta, J.L. Anoxia reoxygenation stimulates collagen type-I and MMP-1 expression in cardiac fibroblasts: modulation by the PPAR-gamma ligand pioglitazone. J. Cardiovasc. Pharmacol., 2004, 44(6), 682-687.
31. Kinugawa, S.; Tsutsui, H.; Hayashidani, S.; Ide, T.; Suematsu, N.; Satoh, S.; Utsumi, H.; Takeshita, A. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ. Res., 2000, 87(5), 392-398.
32. Pacher, P.; Schulz, R.; Liaudet, L.; Szabo, C. Nitrosative stress and pharmacological modulation of heart failure. Trends. Pharmacol. Sci., 2005, 26(6), 302-310.
33. Hare, J.M.; Stamler, J.S. NO/redox disequilibrium in the failing heart and cardiovascular system. J. Clin. Invest., 2005, 115(3), 509-517.
34. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev., 2007, 87(1), 315-424.
35. Dollery, C.M.; McEwan, J.R.; Henney, A.M. Matrix Metalloproteinases and Cardiovascular Disease. Circulation Research, 1995, 77(5), 863.
36. Spinale, F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev., 2007, 87(4), 1285-1342.
37. Kelly, D.; Cockerill, G.; Thompson, M.; Khan, S.; Samani, N.; Squire, I. Plasma metalloproteinase-9 and left ventriclar remodelling after acute myocardial infarction in man: a prospective cohort study. Eur. Heart. J., 2007, 28(6), 711-718.
38. Martos, R.; Baugh, J.; Ledwidge, M.; O'Loughlin, C.; Conlon, C.; Patle, A.; Donelly, S.M.; McDonald, K. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation, 2007, 115(7), 888-895.
39. Kitaoka, H.; Kubo, T.; Okawa, M.; Hayato, K.; Yamasaki, N.; Matsumura, Y.; Doi, Y.L. Impact of metalloproteinases on left ventricular remodeling and heart failure events in patients with hypertrophic cardiomyopathy. Circ. J., 2010, 74(6), 1191-1196.
40. Velho, F.M.; Cohen, C.R.; Santos, K.G.; Silvello, D.; Martinelli, N.; Biolo, A.; Clausell, N.; Rohde, L.E. Polymorphisms of matrix metalloproteinases in systolic heart failure: role on disease susceptibility, phenotypic characteristics, and prognosis. J. Card. Fail., 2011, 17(2), 115-121.
41. Yamazaki, T.; Lee, J.D.; Shimizu, H.; Uzui, H.; Ueda, T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur. J. Heart. Fail., 2004, 6(1), 41-45.
42. Yang, D.C.; Ma, S.T.; Tan, Y.; Chen, Y.H.; Li, D.; Tang, B.; Chen, J.S.; Su, X.H.; Li, G.; Zhang, X.; Yang, Y.J. Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure. Cardiology, 2010, 116(2), 133-141.
43. Gunja-Smith, Z.; Morales, A.R.; Romanelli, R.; Woessner, J.F. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: role of metalloproteinases and pyridinoline cross links. Am. J. Physiol., 1996, 148(5), 1639-1648.
44. Li, Y.Y.; Feldman, A.M.; Sun, Y.; McTiernan, C.F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation, 1998, 98(17), 1728-1734.
45. Thomas, C.V.; Coker, M.L.; Zellner, J.L.; Handy, J.R.; Crumbley, A.J. 3rd.; Spinale, F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation, 1997, 97(17), 1708-1715.
46. Cleutjens, J.P.; Kandala, J.C.; Guarda, E.; Guntaka, R.V.; Weber, K.T. Regulation of collagen degradation in the rat myocardium after infarction. J. Mol. Cell. Cardiol., 1995, 27(6), 1281-1292.
47. Tyagi, S.C.; Kumar, S.G.; Banks, J.; Fortson, W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J. Mol. Cell. Cardiol., 1995, 27(10), 2177-2189.
48. Spinale, F.G.; Coker, M.L.; Krombach, S.R.; Mukherjee, R.; Hallak, H.; Houck, W.V.; Clair, M.J.; Kribbs, S.B.; Johnson, L.L.; Peterson, J.T.; Zile, M.R. Matrix metalloproteinase inhibition during the development of congestive heart failure. Effects on left ventricular dimensions and function. Circ. Res., 1999, 85(4), 364-376.
49. Polyakova, V.; Hein, S.; Kostin, S.; Ziegelhoeffer, T.; Schaper, J. Matrix metalloproteinases and their tissue inhibitors in pressureoverloaded human myocardium during heart failure progression. J. Am. Coll. Cardiol., 2004, 44(8), 1609-1618.
50. Iwanaga, Y.; Aoyama, T.; Kihara, Y.; Onozawa, Y.; Yoneda, T.; Sasayama, S. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J. Am. Coll. Cardiol., 2002, 39(8), 1384-1391.
51. Abou-Raya, S.; Naim, A.; Marzouk, S. Cardiac matrix remodelling in congestive heart failure: the role of matrix metalloproteinases. Clin. Invest. Med., 2004, 27(2), 93-100.
52. Hua, Y.; Song, L.; Wu, N.; Xie, G.; Lu, X.; Fan, X.; Meng, X.; Gu, D.; Yang, Y. Polymorphisms of MMP-2 gene are associated with systolic heart failure prognosis. Clin. Chim. Acta., 2009, 404(2), 119-123.
53. Martos, R.; Baugh, J.; Ledwidge, M.; O'Loughlin, C.; Murphy, N.F.; Conlon, C.; Patle, A.; Donnelly, S.C.; McDonald, K. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur. J. Heart. Fail., 2009, 11(2), 191-197.
54. Dini, F.L.; Buralli, S.; Bajraktari, G.; Elezi, S.; Duranti, E.; Metelli, M.R.; Carpi, A.; Taddei, S. Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease. Biomed. Pharmacother., 2010, 64(5), 339-342.
55. Buralli, S.; Dini, F.L.; Ballo, P.; Conti, U.; Fontanive, P.; Duranti, E.; Metelli, M.R.; Marzilli, M.; Taddei, S. Circulating matrix metalloproteinase- 3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am. J. Cardiol., 2010, 105(6), 853-856.
56. Hessel, M.H.; Bleeker, G.B.; Bax, J.J.; Henneman, M.M.; den Adel, B.; Klok, M.; Schalij, M.J.; Atsma, D.E.; van der Laarse, A. Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur. J. Heart. Fail., 2007, 9(10), 1058-1063.
57. Hunt, S.A.; Abraham, W.T.; Chin, M.H.; Feldman, A.M.; Francis, G.S.; Ganiats, T.G.; Jessup, M.; Konstam, M.A.; Mancini, D.M.; Michl, K.; Oates, J.A.; Rahko, P.S.; Silver, M.A.; Stevenson, L.W.; Yancy, C.W.; Antman, E.M.; Smith, S.C. Jr.; Adams, C.D.; Anderson, J.L.; Faxon, D.P.; Fuster, V.; Halperin, J.L.; Hiratzka, L.F.; Jacobs, A.K.; Nishimura, R.; Ornato, J.P.; Page, R.L.; Riegel, B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112(12), e154-e235.
58. McElmurray, J.H. 3rd.; Mukherjee, R.; New, R.B.; Sampson, A.C.; King, M.K.; Hendrick, J.W.; Goldberg, A.; Peterson, T.J.; Hallak, H.; Zile, M.R.; Spinale, F.G. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. J. Pharmacol. Exp. Ther., 1999, 291(2), 799-811.
59. Reinhardt, D.; Sigusch, H.H.; Hensse, J.; Tyagi, S.C.; Körfer, R.; Figulla, H.R. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart, 2002, 88(5), 525-530.
60. Guo, X.G.; Uzui, H.; Mizuguchi, T.; Ueda, T.; Chen, J.Z.; Lee, J.D. Imidaprilat inhibits matrix metalloproteinase-2 activity in human cardiac fibroblasts induced by interleukin-1beta via NO-dependent pathway. Int. J. Cardiol., 2008, 126(3), 414-420.
61. Sakata, Y.; Yamamoto, K.; Mano, T.; Nishikawa, N.; Yoshida, J.; Hori, M.; Miwa, T.; Masuyama, T. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensinconverting enzyme inhibitor. Circulation, 2004, 109(17), 2143-2149.
62. Sukumaran, V.; Watanabe, K.; Veeraveedu, P.T.; Thandavarayan, R.A.; Gurusamy, N.; Ma, M.; Yamaguchi, K.; Suzuki, K.; Kodama, M.; Aizawa, Y. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertens. Res., 2010, 33(7), 695-702.
63. Ichihara, S.; Noda, A.; Nagata, K.; Obata, K.; Xu, J.; Ichihara, G.; Oikawa, S.; Kawanishi, S.; Yamada, Y.; Yokota, M. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc. Res., 2006, 69(3), 726-735.
64. Nakaya, R.; Uzui, H.; Shimizu, H.; Nakano, A.; Mitsuke, Y.; Yamazaki, T.; Ueda, T.; Lee, J.D. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int. J. Cardiol., 2005, 105(1), 67-73.
65. Cheng, G.; Xu, G.; Cai, H.W.; Wang, H.H.; Bao, X.F. Effect of atorvastatin on non-ischemic heart failure and matrix metalloproteinase- 2 and 9 in rats. Acta. Pharmacol. Sin., 2007, 28(4), 511-517.
66. Tousoulis, D.; Andreou, I.; Tentolouris, C.; Antoniades, C.; Papageorgiou, N.; Gounari, P.; Kotrogiannis, I.; Miliou, A.; Charakida, M.; Trikas, A.; Stefanadis, C. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int. J. Cardiol., 2010, 145(3), 438-443.
67. Song, G.; Hennessy, M.; Zhao, Y.L.; Li, Q.; Han, W.D.; Qi, Y.; Zhao, W.N.; Silke, B.; Barry, M.; Doyle, R.; Spiers, J.P. Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304). Pharmacol. Res., 2006, 54(1), 57-64.
68. Cimmino, G.; Ibanez, B.; Giannarelli, C.; Prat-González, S.; Hutter, R.; Garcia, M.; Sanz, J.; Fuster, V.; Badimon, J.J. Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. Int. J. Cardiol., 2011, 153(3), 256-561.
69. Tziakas, D.N.; Chalikias, G.K.; Hatzinikolaou, H.I.; Stakos, D.A.; Papanas, N.; Tentes, I.K.; Kortsaris, A.X.; Maltezos, E.; Hatseras, D.I.; Kaski J.C. Levosimendan use reduces matrix metalloproteinase- 2 in patients with decompensated heart failure. Cardiovasc. Drugs. Ther., 2005, 19(6), 399-402.
70. Apple, K.A.; Yarbrough, W.M.; Mukherjee, R.; Deschamps, A.M.; Escobar, P.G.; Mingoia, J.T.; Sample, J.A.; Hendrick, J.W.; Dowdy, K.B.; McLean, J.E.; Stroud, R.E.; O'Neill, T.P.; Spinale, F.G. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J. Cardiovasc. Pharmacol., 2006, 47(2), 228-235.
71. Morita, H.; Khanal, S.; Rastogi, S.; Suzuki, G.; Imai, M.; Todor, A.; Sharov, V.G.; Goldstein, S.; O'Neill, T.P.; Sabbah, H.N. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am. J. Physiol. Heart. Circ. Physiol., 2006, 290(6), H2522-2527.
72. Rohde, L.E.; Ducharme, A.; Arroyo, L.H.; Aikawa, M.; Sukhova, G.H.; Lopez-Anaya, A.; McClure, K.F.; Mitchell, P.G.; Libby, P.; Lee, R.T. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation, 1999, 99(23), 3063-3067.
73. Sen, U.; Vacek, T.P.; Hughes, W.M.; Kumar, M.; Moshal, K.S.; Tyagi, N.; Metreveli, N.; Hayden, M.R.; Tyagi, S.C. Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. Pharmacology, 2008, 82(3), 201-213.
74. Mishra, P.K.; Tyagi, N.; Sen, U.; Givvimani, S.; Tyagi, S.C. H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. Am. J. Physiol. Heart. Circ. Physiol., 2010, 298(2), H451-456.
75. Liu, Y.; Huang, H.; Xia, W.; Tang, Y.; Li, H.; Huang, C. NADPH oxidase inhibition ameliorates cardiac dysfunction in rabbits with heart failure. Mol. Cell. Biochem., 2010, 343(1-2), 143-153.
76. Doerries, C.; Grote, K.; Hilfiker-Kleiner, D.; Luchtefeld, M.; Schaefer, A.; Holland, S.M.; Sorrentino, S.; Manes, C.; Schieffer, B.; Drexler, H.; Landmesser, U. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ. Res., 2007, 100(6), 894-903.
77. Guo, D.; Kassiri, Z.; Basu, R.; Chow, F.L.; Kandalam, V.; Damilano, F.; Liang, W.; Izumo, S.; Hirsch, E.; Penninger, J.M.; Backx, P.H.; Oudit, G.Y. Loss of PI3K. enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ. Res., 2010, 107(10), 1275-1289.
78. Song, Y.H.; Li, B.S.; Chen, X.M.; Cai, H. Ethanol extract from Epimedium brevicornum attenuates left ventricular dysfunction and cardiac remodeling through down-regulating matrix metalloproteinase- 2 and -9 activity and myocardial apoptosis in rats with congestive heart failure. Int. J. Mol. Med., 2008, 21(1), 117-124.
79. Wang, Y.; Xu, F.; Chen, J.; Shen, X.; Deng, Y.; Xu, L.; Yin, J.; Chen, H.; Teng, F.; Liu, X.; Wu, W.; Jiang, B.; Guo, D.A. Matrix metalloproteinase-9 induces cardiac fibroblast migration, collagen and cytokine secretion: Inhibition by salvianolic acid B from Salvia miltiorrhiza. Phytomedicine, 2011, 19(1), 13-19.
80. Tian, H.; Huang, M.L.; Liu, K.Y.; Jia, Z.B.; Sun, L.; Jiang, S.L.; Liu, W.; Kinkaid, H.Y.; Wu, J.; Li, R.K. Inhibiting matrix metalloproteinase by cell-based TIMP-3 gene transfer effectively treats acute and chronic ischemic cardiomyopathy. Cell. Transplant., 2011 Sep. 23.
81. Mias, C.; Lairez, O.; Trouche, E.; Roncalli, J.; Calise, D.; Seguelas, M.H.; Ordener, C.; Piercecchi-Marti, M.D.; Auge, N.; Salvayre, A.N.; Bourin, P.; Parini, A.; Cussac, D. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells, 2009, 27(11), 2734-2743.
82. Premaratne, G.U.; Ma, L.P.; Fujita, M.; Lin, X.; Bollano, E.; Fu, M. Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: anti-inflammatory role. J. Cardiothorac. Surg., 2011, 6, 43.
83. Park, H.; Larson, B.L.; Guillemette, M.D.; Jain, S.R.; Hua, C.; Engelmayr, G.C. Jr.; Freed, L.E. The significance of pore microarchitecture in a multi-layered elastomeric scaffold for contractile cardiac muscle constructs. Biomaterials, 2011, 32(7), 1856-1864.